IP Verse

Compositions Comprising 5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Use In Treating Mental Disorders

Patent No. EP3927338 (titled "Compositions Comprising 5-Methoxy-N,N-Dimethyltryptamine (5-Meo-Dmt) For Use In Treating Mental Disorders") was filed by GH Research Ireland on Feb 24, 2020. The application was issued on Oct 9, 2024.

Patent Summary

Treatment of major depressive disorder using 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered via intravenous, intramuscular, or subcutaneous routes. The treatment involves administering a therapeutically effective amount of 5-MeO-DMT to induce a peak psychedelic experience, which is believed to drive therapeutic benefit. The treatment is particularly effective for patients with treatment-resistant depression, suicidal ideation, and other mental disorders characterized by disrupted brain connectivity networks.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANJul 9, 2025CMS CAMERON MCKENNA NABARRO OLSWANG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3927338

GH RESEARCH IRELAND
Application Number
EP20710060A
Filing Date
Feb 24, 2020
Status
Granted And Under Opposition
Sep 6, 2024
Publication Date
Oct 9, 2024
External Links
Slate, Register , Google Patents